Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHUK | O15111 | 15/20 | 0.62 |
| ▸ | ICOSLG | O75144 | 10/20 | 0.60 |
| ▸ | ICOS | Q9Y6W8 | 10/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | IKBKB | O14920 | 1/20 | 0.57 |
| ▸ | PIM1 | P11309 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.57 |
| ▸ | IKBKG | Q9Y6K9 | 1/20 | 0.57 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12619326 | 0.98 | CHUK (0.62) | CHUKICOSLGICOSMEN1IKBKB | |
| SCHEMBL1797661 | 0.98 | CHUK (0.62) | CHUKICOSLGICOSMEN1IKBKB | |
| SCHEMBL13376960 | 0.85 | CHUK (0.69) | CHUKICOSLGICOSMEN1IKBKB | |
| SCHEMBL1800865 | 0.81 | CHUK (0.59) | CHUKICOSLGICOSMEN1IKBKB | |
| SCHEMBL12619301 | 0.80 | CHUK (0.58) | CHUKICOSLGICOSMEN1IKBKB | |
| SCHEMBL1799701 | 0.80 | CHUK (0.58) | CHUKICOSLGICOSMEN1IKBKB | |
| SCHEMBL13377022 | 0.78 | CHUK (0.62) | CHUKICOSLGICOSMEN1IKBKB | |
| SCHEMBL14253071 | 0.78 | CHUK (0.62) | CHUKICOSLGICOSMEN1IKBKB | |
| SCHEMBL13377061 | 0.78 | CHUK (0.61) | CHUKICOSLGICOSMEN1IKBKB | |
| SCHEMBL13452572 | 0.78 | CHUK (1.00) | CHUKICOSLGICOSMEN1IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951801-B2 | For therapy of inflammatory disease and cancer | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-7951801-B2 | For therapy of inflammatory disease and cancer | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-7951801-B2 | For therapy of inflammatory disease and cancer | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| EP-2206713-A1 | Beta-carbolines useful for treating inflammatory disease | Millennium Pharmaceuticals, Inc. (US) | 2010-07-14 | — | — | EP | disclosed |
| US-7727985-B2 | Beta-carbolines useful for treating inflammatory disease | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-7727985-B2 | Beta-carbolines useful for treating inflammatory disease | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20100093713-A1 | BETA-CARBOLINES USEFUL FOR TREATING INFLAMMATORY DISEASE | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093713-A1 | BETA-CARBOLINES USEFUL FOR TREATING INFLAMMATORY DISEASE | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093713-A1 | BETA-CARBOLINES USEFUL FOR TREATING INFLAMMATORY DISEASE | NFKBIA, NFKB2, IKBKG | CHUK 8/4885ICOSLG 2200/4885ICOS 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.